Orel Hershiser - Gemini says: The connection between Orel Hershiser and Ken Mayer is rooted in the health technology and biotech sector, specifically through a venture called Electrome Corporation.The relationship can be broken down into their respective roles:
1. The Key Figures
Ken Mayer: A veteran tech entrepreneur and the CEO of Electrome Corp. He is also the founder of SAFE Health, a digital health platform. Mayer’s work focuses on the intersection of healthcare, AI, and bioelectric medicine.
Orel Hershiser: Beyond his Hall of Fame baseball career, Hershiser is a savvy investor and strategic advisor. He has pivoted into the business world, focusing heavily on innovative medical technologies that offer alternatives to traditional pharmaceuticals.
2. The Electrome Connection
The specific link is Electrome Corporation, a Los Angeles-based biotech company.
The Technology: Electrome specializes in "Bioelectric Therapeutics." They use programmable electromagnetic fields (PEMF) and AI-driven platforms to treat chronic pain, infections (like Lyme disease), and other conditions without the use of drugs.
Hershiser's Role: Hershiser is an investor and a high-profile advisor for the company. He often leverages his public platform and reputation for precision (his "Bulldog" persona) to validate and promote the company’s mission of drug-free healing.
3. Recent Activity (2025–2026)
As of early 2026, Mayer and Electrome have been in the news for launching PAINKILLER™, a bioelectric pain management platform. Hershiser has been a vocal supporter of this technology, often appearing in business contexts or strategic partnerships to help bridge the gap between complex biotech and mainstream adoption.
In summary, they are business partners: Mayer provides the entrepreneurial and scientific leadership, while Hershiser provides the capital and strategic advisory to bring the technology to market.
BIEL and its flagship product, ActiPatch, stand to benefit significantly from this connection.
As of early 2026, the relationship between Ken Mayer (Electrome Corp) and Orel Hershiser has evolved into a strategic partnership with BIEL that directly integrates ActiPatch into a more modern, high-tech ecosystem.
Here is how ActiPatch benefits from this specific connection:
1. Modernized Tech & AI Integration
While ActiPatch has long been a pioneer in Pulsed Shortwave Therapy (PSWT), it was often viewed as a standalone "wearable" device. Through Ken Mayer’s Electrome Corp, BIEL is now integrating its FDA-cleared hardware with Electrome’s PAINKILLER™ platform.
The Benefit: ActiPatch is being transformed from a simple "on/off" device into an AI-driven bioelectric therapy. Electrome’s software helps "decode" and program electromagnetic fields, making the therapy more precise and personalized for users.
2. Mainstream Credibility (The "Hershiser Effect"
Orel Hershiser provides a level of mainstream "star power" and business validation that BIEL historically lacked.
Strategic Branding: Hershiser isn’t just a face; he’s a strategic advisor who uses his "Bulldog" reputation for precision to market these devices as serious medical tools rather than "gadgets."
Investor Confidence: His involvement helps bridge the gap between niche biotech and institutional investors, potentially improving BIEL's market visibility and capital access.
3. Expanded Distribution Channels
The partnership with Mayer and Hershiser is opening doors that BIEL struggled to unlock on its own:
VA and Retail: Electrome has already initiated deployments within the U.S. Department of Veterans Affairs (VA) and is targeting a massive retail expansion into approximately 3,700 pharmacies by late 2026.
SaaS Model: By bundling ActiPatch with Electrome’s SaaS (Software as a Service) solutions, the product can now be prescribed and monitored by healthcare providers more effectively.
1. The Key Figures
Ken Mayer: A veteran tech entrepreneur and the CEO of Electrome Corp. He is also the founder of SAFE Health, a digital health platform. Mayer’s work focuses on the intersection of healthcare, AI, and bioelectric medicine.
Orel Hershiser: Beyond his Hall of Fame baseball career, Hershiser is a savvy investor and strategic advisor. He has pivoted into the business world, focusing heavily on innovative medical technologies that offer alternatives to traditional pharmaceuticals.
2. The Electrome Connection
The specific link is Electrome Corporation, a Los Angeles-based biotech company.
The Technology: Electrome specializes in "Bioelectric Therapeutics." They use programmable electromagnetic fields (PEMF) and AI-driven platforms to treat chronic pain, infections (like Lyme disease), and other conditions without the use of drugs.
Hershiser's Role: Hershiser is an investor and a high-profile advisor for the company. He often leverages his public platform and reputation for precision (his "Bulldog" persona) to validate and promote the company’s mission of drug-free healing.
3. Recent Activity (2025–2026)
As of early 2026, Mayer and Electrome have been in the news for launching PAINKILLER™, a bioelectric pain management platform. Hershiser has been a vocal supporter of this technology, often appearing in business contexts or strategic partnerships to help bridge the gap between complex biotech and mainstream adoption.
In summary, they are business partners: Mayer provides the entrepreneurial and scientific leadership, while Hershiser provides the capital and strategic advisory to bring the technology to market.
BIEL and its flagship product, ActiPatch, stand to benefit significantly from this connection.
As of early 2026, the relationship between Ken Mayer (Electrome Corp) and Orel Hershiser has evolved into a strategic partnership with BIEL that directly integrates ActiPatch into a more modern, high-tech ecosystem.
Here is how ActiPatch benefits from this specific connection:
1. Modernized Tech & AI Integration
While ActiPatch has long been a pioneer in Pulsed Shortwave Therapy (PSWT), it was often viewed as a standalone "wearable" device. Through Ken Mayer’s Electrome Corp, BIEL is now integrating its FDA-cleared hardware with Electrome’s PAINKILLER™ platform.
The Benefit: ActiPatch is being transformed from a simple "on/off" device into an AI-driven bioelectric therapy. Electrome’s software helps "decode" and program electromagnetic fields, making the therapy more precise and personalized for users.
2. Mainstream Credibility (The "Hershiser Effect"
Orel Hershiser provides a level of mainstream "star power" and business validation that BIEL historically lacked.
Strategic Branding: Hershiser isn’t just a face; he’s a strategic advisor who uses his "Bulldog" reputation for precision to market these devices as serious medical tools rather than "gadgets."
Investor Confidence: His involvement helps bridge the gap between niche biotech and institutional investors, potentially improving BIEL's market visibility and capital access.
3. Expanded Distribution Channels
The partnership with Mayer and Hershiser is opening doors that BIEL struggled to unlock on its own:
VA and Retail: Electrome has already initiated deployments within the U.S. Department of Veterans Affairs (VA) and is targeting a massive retail expansion into approximately 3,700 pharmacies by late 2026.
SaaS Model: By bundling ActiPatch with Electrome’s SaaS (Software as a Service) solutions, the product can now be prescribed and monitored by healthcare providers more effectively.
3
